Stereoselective protection of exogenous and endogenous atrial natriuretic factor by enkephalinase inhibitors in mice and humans

What Was Tested

This randomized controlled trial paper looks at ANP (Atrial Natriuretic Peptide).

The researchers compared the relative potencies of sinorphan and retorphan, the S- and R-enantiomers of acetorphan a potent inhibitor of enkephalinase (EC 3.4.34.11), to inhibit membrane metalloendopeptidase in vivo and to protect exogenous and endogenous ANF after oral administration.

In mice, sinorphan was 2-3 fold as potent as retorphan in inhibiting the specific in vivo binding of [3H]acetorphan to kidney enkephalinase.

Who Took Part

PubMed indexes the participants as adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this ANP (Atrial Natriuretic Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received ANP (Atrial Natriuretic Peptide).

A placebo (an inactive look-alike) gave the ANP (Atrial Natriuretic Peptide) group a baseline to be compared against.

What Was Measured

The same potency ratio was found for the enhancement of trichloroacetic acid-precipitated radioactivity in kidneys of mice that had received 125I-ANF, which is used as a test for the protection of the hormone against inactivation in vivo.

The subject headings attached to it are Atrial Natriuretic Factor, Binding, Competitive, Chemical Phenomena, Chemistry, Cyclic GMP, Kidney and Mice.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of ANP (Atrial Natriuretic Peptide).

The publication is from 1990 (European journal of pharmacology), a journal based in Netherlands.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.